Current Environment:

Researcher | Research Overview

Over the last several decades, there have been dramatic improvements in the treatment of the most common types of pediatric cancers. However, despite these successes, relapsed or refractory leukemia carry a dismal prognosis. For example, more children will succumb to relapsed acute lymphoblastic leukemia that any other type of pediatric malignancy. It is paramount that novel agents and treatment strategies are developed for these cancers that improve outcomes while limiting both the acute and long-term toxicities of therapy.

In order to achieve these goals, we are developing a robust translational program supported by our own world-class basic science laboratories, extensive collection of clinical samples and well-known expertise in clinical trial design and administration. By encouraging collaborations within academia and industry we foster pre-clinical evaluation of the most compelling novel therapies as a mechanism to stream line their introduction into early phase clinical trials.

Researcher | Research Background

Dr. Place received his PhD in Pharmacology and Toxicology from Dartmouth College in 2004 and his MD from the Dartmouth Medical School in 2006. He completed his pediatric residency training in the Boston Combined Residency Program at Boston Children’s Hospital and Boston Medical Center. He subsequently completed a fellowship in pediatric hematology-oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute. In 2012, he became an attending physician in Pediatric Oncology at the Dana-Farber/Children’s Hospital Cancer Center, where he currently participates in the development of early phase clinical trials in the Pediatric Hematologic Malignancy Service.


Researcher | Publications